PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis

Lignende værker

• Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
  af: Ruperto, N, et al.
  Udgivet: (2011)
• Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
  af: Lovell, Daniel J, et al.
  Udgivet: (2020)
• 7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
  af: Ruperto, N, et al.
  Udgivet: (2008)
• PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
  af: Kingsbury, D, et al.
  Udgivet: (2013)
• PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
  af: De Benedetti, F, et al.
  Udgivet: (2013)